Is endoscopic gastric fundoplication appropriate for a patient with LA grade B esophagitis, Hill grade 3–4 gastro‑esophageal flap valve, mild‑moderate gastritis, no hiatal hernia, and refractory to proton pump inhibitor (PPI) therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Endoscopic Gastric Fundoplication is NOT Indicated for This Patient

Based on current evidence, this patient is NOT an appropriate candidate for endoscopic fundoplication due to the presence of Hill grade 3-4 gastroesophageal flap valve and the discrepancy regarding hiatal hernia status. The patient should instead be evaluated for laparoscopic fundoplication if objective evidence of pathologic reflux is confirmed.

Critical Patient Selection Criteria for Endoscopic Fundoplication

The most important determinant of success with transoral incisionless fundoplication (TIF) is proper patient selection. Ideal candidates must have:

  • Hill grade 1 or 2 gastroesophageal flap valve 1
  • Small (<2 cm) or no hiatal hernia 1, 2, 3
  • Objective evidence of pathologic GERD (positive pH-metry or endoscopy) 2

Why This Patient Does Not Qualify

Your patient has Hill grade 3-4 flap valve, which falls outside the accepted criteria. Hill grade 3-4 indicates significant anatomic disruption of the gastroesophageal junction 4. Research demonstrates that Hill grade correlates with LES pressure, acid exposure time, and reflux severity—higher Hill grades are associated with worse outcomes 4.

Additionally, there is conflicting documentation regarding hiatal hernia (pH capsule notes Hill 3, endoscopy notes Hill 4 with "no H.H"). This discrepancy requires clarification, as the presence of hiatal hernia significantly impacts treatment selection 5.

Appropriate Management Algorithm

Step 1: Confirm Objective GERD Evidence

Before considering any invasive therapy in PPI-refractory patients, you must document:

  • Abnormal esophageal acid exposure on pH-impedance monitoring (>6% time pH <4) 2
  • Positive symptom-reflux association for regurgitation 2

Step 2: Surgical Evaluation

Laparoscopic fundoplication is the appropriate invasive option for this patient with:

  • Documented PPI failure
  • LA grade B esophagitis (objective GERD evidence)
  • Hill grade 3-4 (anatomically disrupted GEJ)

Expert consensus from 2018 deems laparoscopic fundoplication appropriate for elevated esophageal acid exposure and moderately appropriate for positive symptom-reflux association with regurgitation and large hiatal hernia 2. The 2016 Asia-Pacific guidelines confirm that surgery in experienced hands is a treatment option for patients with refractory GERD symptoms failing medical therapy, but only when there is objectively documented gastroesophageal reflux 6.

Step 3: Consider Modified Endoscopic Approaches (If Surgery Declined)

If the patient refuses surgery, concomitant TIF with hiatal hernia repair (cTIF) addresses both the crural diaphragm and GEFV 1. However, this remains investigational for Hill grade 3-4 patients.

Critical Pitfalls to Avoid

  1. Do not proceed with standard TIF in Hill grade 3-4 patients—the anatomic disruption predicts poor outcomes 1, 4

  2. Clarify the hiatal hernia status—the discrepancy between pH capsule (Hill 3) and endoscopy (Hill 4, no HH) must be resolved, as hiatal hernia presence negatively correlates with endoscopic fundoplication efficacy 5

  3. Verify true PPI failure—ensure adequate dosing (twice daily), duration (≥8 weeks), and compliance before labeling as refractory 7

  4. Address the gastritis—moderate antral gastritis may contribute to symptoms and should be managed (H. pylori testing if not done, consider mucosal protective agents)

Evidence Quality Considerations

The 2006 AGA guideline 8 noted that endoscopic therapies showed modest effects on LES pressure and acid exposure, with normalization being "the exception rather than the rule." Importantly, sham-controlled trials demonstrated striking placebo response rates, and serious adverse events led to withdrawal of some devices from the market.

More recent evidence from 2023 1 shows evolution in patient selection, emphasizing that TIF stands out in its ability to recreate optimal GEFV—but only in appropriately selected patients with Hill grade 1-2 and minimal/no hiatal hernia.

The 2018 expert panel 2 using RAND/UCLA methodology found that transoral incisionless fundoplication was not judged appropriate in any PPI-refractory scenario they evaluated, while laparoscopic fundoplication received appropriate ratings for elevated acid exposure.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.